- Home
- BMY
as 04-02-2025 4:00pm EST
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
| Founded: | 1887 | Country: | United States |
| Employees: | N/A | City: | PRINCETON |
| Market Cap: | 120.5B | IPO Year: | N/A |
| Target Price: | $58.00 | AVG Volume (30 days): | 12.2M |
| Analyst Decision: | Hold | Number of Analysts: | 14 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | -4.41 | EPS Growth: | N/A |
| 52 Week Low/High: | $39.35 - $63.33 | Next Earning Date: | 04-24-2025 |
| Revenue: | $48,300,000,000 | Revenue Growth: | 7.32% |
| Revenue Growth (this year): | -4.64% | Revenue Growth (next year): | -5.82% |
Latest Bristol-Myers Squibb Company News
BMY Breaking Stock News: Dive into BMY Ticker-Specific Updates for Smart Investing
Motley Fool
20 hours ago
Is Bristol Myers Squibb's High-Yielding Dividend Safe?
Zacks
a day ago
CHMP Issues Positive Opinion for Label Expansion of BMY's Opdivo
Zacks
2 days ago
Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report?
Insider Monkey
2 days ago
Is Bristol-Myers Squibb (BMY) One of the Best Healthcare Stocks to Buy According to Billionaires?
Zacks
2 days ago
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Motley Fool
2 days ago
Beat the S&P 500 With This Cash-Gushing Dividend Stock
Insider Monkey
2 days ago
Bristol-Myers Squibb Company (BMY): Among the Best High Yield Stocks to Buy in April for Dividend Capture
Insider Monkey
5 days ago
Jim Cramer on Bristol-Myers Squibb. Co (NYSE:BMY): They Should Have Known Better
Compare BMY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BMY Bristol-Myers Squibb Company - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.